Table 3.

Comparison of pretreatment clinical T stage (cT) with pathologic stage at extirpative surgery (ypT) for 76 evaluable cases.

Group\Number	n	ypT0	ypT0-2
All	76	21 (28%)	53 (70%)
cT stage
cT3	69	20 (29%)	49 (71%)
cT4	7	1 (14%) P=NS	4 (57%) P=NS
Interval from day 1 radiation therapy to surgery
≤17 weeks	35	10 (29%)	26 (74%)
>17 weeks	41	11 (27%) P=NS	27 (66%) P=NS
PROSPECT eligible?*
Y	38	16 (42%)	33 (87%)
N	38	5 (13%) P=.009	20 (53%) P=.002
Clinical score‡
0	18	7 (39%)	16 (89%)
1	48	13 (27%)	35 (73%)
2	10	1 (10%) P=NS	2 (20%) P=.0008 CS2 vs CS0,1

Statistical significance estimated by Fisher exact test.

^*PROSPECT eligible: disease extent eligible for recently activated (N1048) trial (comparing preoperative RT+5FU vs FOLFOX): location at ≥5 cm, no disease ≤3 mm from mesorectal fascia, and cT <cT4.

^‡Clinical score (CS) based on 4 adverse pretreatment findings: site <5 cm from verge, tethered or fixed to palpation, circumferential, near obstructing. CS0: 0 adverse factors; CS1: 1or 2 adverse factors; CS2: 3 or 4 adverse factors.